This product is a EGFP encoding oncolytic vaccinia virus, which is based on VACV-WR with E3L deleted.Protein E3 plays a role in the inhibition of multiple cellular antiviral responses activated by dsRNA, such as inhibition of PKR activation, apoptosis, and IFN-mediated antiviral activities.The TNFSF9 has been shown to reactivate anergic T lymphocytes in addition to promoting T lymphocyte proliferation.The deletion of E3L and oncolytic-rendered modifications could enhance an immune response to a poxvirus vaccine.This product can be used in oncolytic virotherapy research and vaccinie application.
Specifications
Family
Poxviridae
Species
Vaccinia virus
Serotype
Western Reserve
Backbone
VACV-WR(ΔE3L)
Backbone Background
VACV-WR strain derived from Wyeth through passaging in mice and shown high tumor selectivity and strong oncolytic effect in mouse models.The engineered VACV-WR could further enhance the immune activity and the efficacy of cancer therapies.
Gene Modification
ΔE3L
Promoter
pSE
Transgene
EGFP
Type of Transgene
Reporter gene
Related Target/Protein
Enhanced green fluorescent protein
Capsid Modification
None
Titer
>1*10^8 PFU
Related Diseases
Breast cancer, Prostate cancer, Colon cancer, Cancer vaccine
EGFP, derived from Aequorea victoria, is a unique GFP variant which contains chromophore mutations that make the protein 35 times brighter than wild-type GFP, and is codon-optimized for higher expression in mammalian cells. These changes in the GFP coding sequence provide an enhanced GFP (EGFP) that greatly increases the sensitivity of the reporter protein.
Customer Reviews and Q&As
There are currently no customer reviews or questions for EGFP-encoding Oncolytic Vaccinia Virus Western Reserve (ΔE3L), pSE-(EGFP) (RepOV-0014WQ). Click the button below to contact us or submit your feedback about this product.
All products and services are for Research Use Only. Not For Clinical Use.
Datasheet